ESMO Daily Reporter

The ESMO Daily Reporter is the official publication of ESMO, delivering coverage of scientific developments from the Society's events. It offers insights and updates on important issues in the field of oncology.

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

N/A

Country

N/A

Articles

Innovation means progress for all people with cancer

Jan 8, 2025 | dailyreporter.esmo.org | Dario Trapani

Innovation in oncology is not a luxury, rather a necessity. Yet, it is not the mere presence of technology or novel therapies that defines true innovation, but the value they bring to patients and, by extent, to the society as a whole. If innovation does not tangibly improve lives or address inequities, it may be perceived just like a playful toy.
Innovation is leading to a comprehensive ‘map’ of tumours

Oct 16, 2024 | dailyreporter.esmo.org | Joakim Lundeberg

For many decades, our understanding of the spatial biology of tumours came only from microscopy, for example, using immunohistochemistry to identify specific proteins within a tumour section. However, advances in spatial transcriptomics technology mean that we can now pinpoint which genes are active within different parts of the tumour and its microenvironment.
Molecular Analysis for Precision Oncology Congress (MAP) 2024

Oct 16, 2024 | dailyreporter.esmo.org | Joakim Lundeberg

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
The expanding toolbox for immuno-oncology

Oct 8, 2024 | dailyreporter.esmo.org | Elena Garralda

Unleashing the true power of immunotherapy in oncology is still challenging. While immunotherapeutic strategies continue to transform the cancer treatment landscape by improving outcomes and the long-term outlook for many patients, only subsets of cancer patients currently derive benefit from them and response rates vary across different tumour types.
an option with challenges

Oct 1, 2024 | dailyreporter.esmo.org | Dario Trapani

The development and approval of oncology medicines are multifaced processes which encompass patient needs and market dynamics to accelerate the accessibility to highly effective therapies while simultaneously ensuring a viable business model for the industry (JCO Glob Oncol. 2023 Sep:9:e2300294). Clinical trial populations often fail to accurately reflect the broader patient populations encountered in real-world settings — a discrepancy that has been long recognised (Lancet Reg Health Eur.
Rising rates of cancer in young people: nature or nurture?

Sep 16, 2024 | dailyreporter.esmo.org | Shuji Ogino

The incidence of early-onset cancer (EOC), or cancer occurring in adults younger than 50 years of age, has increased by almost 80% since the 1990s, alongside a substantial (27.7%) increase in deaths from cancer in this age group (BMJ Oncology. 2023;2:e000049). What is driving this increased incidence of EOC? For some cancers, this may be due to an increased uptake of screening and early detection, such as for prostate and thyroid cancers (Nat Rev Clin Oncol. 2022;19:656–673).
promising potential

Sep 15, 2024 | dailyreporter.esmo.org | Tobias Weiss

Immunotherapy of brain tumours remains a promising treatment strategy given the limited efficacy of current treatments for these tumours and the groundbreaking success of immunotherapy for extracranial malignancies. However, clinical trials of immunotherapy for the treatment of primary brain tumours, predominantly glioma, have not yet conferred a survival benefit compared with conventional cancer treatments.
Multi-cancer early detection - promise or reality?

Sep 15, 2024 | dailyreporter.esmo.org | Maximilian Diehn

Multi-cancer early detection (MCED) tests promise to screen for multiple cancer types at the same time using a simple blood draw, potentially enabling detection of cancers without using current screening approaches and augmenting traditional screening methods such as mammography or low-dose CT scanning. Importantly, they hold the promise of diagnosing patients earlier, when the chance for cure is higher.
Liquid biopsy plays a growing role in early-stage lung cancer

Sep 14, 2024 | dailyreporter.esmo.org | Umberto Malapelle

Despite the recent improvements in the management of lung cancer, the vast majority of patients still experience poor clinical outcomes mainly due to challenges in early detection, the high risk of metastasis, and the development of resistance to multiple therapies. However, great strides have been made with the introduction of liquid biopsy in the diagnostic algorithm for this population (J Thorac Oncol. 2021;16:1647–1662; Lung Cancer. 2022;172:53–64).
How to mark a tangible impact in cancer control

Aug 14, 2024 | dailyreporter.esmo.org | Dario Trapani

With a recent release, the International Agency for Research on Cancer (IARC), the specialised cancer agency of the World Health Organization (WHO), has portrayed the current landscape of cancer epidemiology worldwide (CA Cancer J Clin. 2024 May-Jun;74(3):229-263). Data reported a grim picture, with nearly 20 million new cancer cases, including nonmelanoma skin cancers, accompanied by 9.7 million deaths.